Fatal anaphylactic reaction due to ferric carboxymaltose: A case report

References (7)

1. Friedrisch JR, Cançado RD. Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia. Rev Bras Hematol Hemoter 2015; 37: 400-5
2. Gafter-Gvili A, Schechter A, Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol 2019; 142: 44-50
3. EMA-CHMP. Assessment report for: iron containing intravenous (IV) medicinal products EMA/549569/2013,2013 (last accessed 10 February 2020). Available at; URL: http://www.ema.europa.eu/ docs/en_GB/document_library/ Referrals-document / IV_iron_31/ WC500150771.pdf 4. Scott LJ. Ferric Carboxymaltose: A Review in Iron Deficiency. Drugs 2018; 78: 479-93
4. Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S. Evaluation of the reported rates of severe hypersensitivity reactions associated with ferric carboxymaltose and iron (III) isomaltoside 1000 in Europe based on data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug Saf 2019; 42: 463-71
5. Mulder MB, van den Hoek HL, Birnie E, van Tilburg AJP, Westerman EM. Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside-1000 (Monofer®) versus ferric carboxy-maltose (Ferinject®). A single center, cohort study. Br J Clin Pharmacol 2019; 85: 385-92
6. Ferinject (ferric carboxymaltose). Uptating 13 November 2019. (last accessed 10 February 2020). Available at; URL: https://www.medicines. org.uk/emc/product/5910/smpc 8. FDA-CDER. Injectafer (VIT-45, ferric carboxymaltose injection; FCM) for the treatment of iron deficiency anemia. Updated clinical safety information (last accessed 10 February 2020). Available at; URL: https://www.accessdata.fda.gov/drugsatfda_docs/ nda/2013/203565Orig1s000MedR.pdf 9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975
7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Adverse Drug Reaction Probability Scale (Naranjo) in Drug Induced Liver Injury (last accessed 10 February 2020). Available at; URL: https://www.ncbi.nlm.nih.gov/books/NBK548069/